Everest Clinical Research, a portfolio company of Arlington Capital Partners, has acquired the Biometrics and Data Services business unit of Firma Clinical Research, known as Firma DS, for undisclosed terms. The deal expands Everest's global biometrics expertise and clinical data science capabilities. Firma DS provides biometrics and clinical data services to biotechnology, pharmaceutical, medical device and diagnostic companies, supporting more than 1,000 clinical studies and over 60 New Drug Application submissions across complex therapeutic areas including oncology, neurology, rare disease, hepatology and nephrology.

As part of the acquisition, an experienced team of biometrics professionals will join Everest's global organization, strengthening the company's delivery capabilities across the US and Asia-Pacific. Existing Firma DS clients will gain access to Everest's global delivery infrastructure and scale, advanced technology platforms, and full-service clinical development capabilities, including regulatory strategy, clinical operations, clinical trial technologies, medical affairs, patient safety and medical writing, through a single global contract research organization partner. "As clinical development grows more global and complex, sponsors need partners with the scale, expertise, and integrated capabilities to support programs across geographies and regulatory environments," said Malcolm Little, a partner at Arlington Capital Partners. "This acquisition strengthens Everest's ability to meet that need and support clients worldwide.".